Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation

被引:5227
作者
Lip, Gregory Y. H. [1 ]
Nieuwlaat, Robby [2 ]
Pisters, Ron [2 ]
Lane, Deirdre A. [1 ]
Crijns, Harry J. G. M. [2 ]
机构
[1] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham B18 7QH, W Midlands, England
[2] Maastricht Univ, Dept Cardiol, Med Ctr, Maastricht, Netherlands
关键词
LOW-DOSE ASPIRIN; ISCHEMIC-STROKE; ANTITHROMBOTIC TREATMENT; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; PREVENTION; THERAPY; GENDER; ANTICOAGULATION; PROGRESSION;
D O I
10.1378/chest.09-1584
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts. Thus, many potential risk factors have not been included. Methods: We refined the 2006 Birmingham/National Institute for Health and Clinical Excellence (NICE) stroke risk stratification schema into a risk factor-based approach by reclassifying and/or incorporating additional new risk factors where relevant. This schema was then compared with existing stroke risk stratification schema in a real-world cohort of patients with AF (n = 1,084) from the Euro Heart Survey for AF. Results: Risk categorization differed widely between the different schemes compared. Patients classified as high risk ranged from 10.2% with the Framingham schema to 75.7% with the Biramingham 2009 schema. T he classic CHADS(2), (Congestive heart failure, Hypertension, Age > 75, Diabetes, prior Stroke/transient isehemic attack) schema categorized the largest proportion (61.9%) into the intermediate-risk strata, whereas the Birmingham 2009 schema classified 15.1% into this category. The Birmingham 2009 schema classified only 9.2% as low risk, whereas the Framingham scheme categorized 48.3% as low risk. Calculated C-statistics suggested modest predictive value of all schema for TE. The Birmingham 2009 schema fared marginally better (C-statistic, 0.606) than CHADS(2). However, those classified as low risk by the Birmingham 2009 and NICE schema were truly low risk with no TE events recorded, whereas TE events occurred in 1.4% of low-risk CHADS(2) subjects. When expressed as a scoring system, the Birmingham 2009 schema (CHA(2)DS(2)-VASc acronym) showed an increase in TE rate with increasing scores (P value for trend = .003). Conclusion: Our novel, simple stroke risk stratification schema, based on a risk factor approach, provides some improvement in predictive value for TE over the CHADS(2) schema, with low event rates in low-risk subjects and the classification of only a small proportion of subjects into the in(intermediate-risk category. This schema could improve our approach to stroke risk stratification in patients with AF. CHEST 2010; 137(2):263-272
引用
收藏
页码:263 / 272
页数:10
相关论文
共 34 条
  • [1] [Anonymous], ATR FIBR NAT CLIN GU
  • [2] [Anonymous], 1993, J STROKE CEREBROVASC
  • [3] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [4] Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
    Baruch, Lawrence
    Gage, Brian F.
    Horrow, Jay
    Juul-Moller, Steen
    Labovitz, Arthur
    Persson, Maria
    Zabalgoitia, Miguel
    [J]. STROKE, 2007, 38 (09) : 2459 - 2463
  • [5] The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
    Belch, Jill
    MacCuish, Angus
    Campbell, Iain
    Cobbe, Stuart
    Taylor, Roy
    Prescott, Robin
    Lee, Robert
    Bancroft, Jean
    MacEwan, Shirley
    Shepherd, James
    Macfarlane, Peter
    Morris, Andrew
    Jung, Roland
    Kelly, Christopher
    Connacher, Alan
    Peden, Norman
    Jamieson, Andrew
    Matthews, David
    Leese, Graeme
    McKnight, John
    O'Brien, Iain
    Semple, Colin
    Petrie, John
    Gordon, Derek
    Pringle, Stuart
    MacWalter, Ron
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 : a1840
  • [6] Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
    Connolly, Stuart J.
    Pogue, Janice
    Eikelboom, John
    Flaker, Gregory
    Commerford, Patrick
    Franzosi, Maria Grazia
    Healey, Jeffrey S.
    Yusuf, Salim
    [J]. CIRCULATION, 2008, 118 (20) : 2029 - 2037
  • [7] Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the west Birmingham atrial fibrillation project)
    Conway, DSG
    Lip, GYH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (11) : 1422 - 1425
  • [8] Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe -: A report from the Euro Heart Survey on atrial fibrillation
    Dagres, Nikolaos
    Nieuwlaat, Robby
    Vardas, Panos E.
    Andresen, Dietrich
    Levy, Samuel
    Cobbe, Stuart
    Kremastinos, Dimitrios Th.
    Breithardt, Guenter
    Cokkinos, Dennis V.
    Crijns, Harry J. G. M.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (05) : 572 - 577
  • [9] Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation
    Fang, Margaret C.
    Go, Alan S.
    Chang, Yuchiao
    Borowsky, Leila
    Pomernacki, Niela K.
    Singer, Daniel E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (08) : 810 - 815
  • [10] Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation - The AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study
    Fang, MC
    Singer, DE
    Chang, YC
    Hylek, EM
    Henault, LE
    Jensvold, NG
    Go, AS
    [J]. CIRCULATION, 2005, 112 (12) : 1687 - 1691